Quercetin's Effect on Bone Health and Inflammatory Markers

Kennesaw State University

Status

Completed

Conditions

Osteoporosis, Postmenopausal

Treatments

Dietary Supplement: Quercetin (500 mg)

Other: Placebo (500 mg)

Study type

Interventional

Funder types

Other

Identifiers

NCT05371340

19-476

Details and patient eligibility

About

Quercetin is a plant-based flavonoid that is naturally found in many fruits and vegetables, and is considered to be a potent antioxidant with several expected health benefits such as anti-inflammatory effects and bone-conserving properties. Participants will supplement with either Quercetin, or placebo, for 90-days with pre- and post-testing visits.

Full description

Quercetin is a plant-based flavonoid that is naturally found in many fruits and vegetables such as onions, apples, berries, green tea, and red wine and is currently an FDA approved supplement. Quercetin is considered to be a potent antioxidant with several expected health benefits. Both in vivo and in vitro studies have demonstrated that quercetin acts as a potent natural osteogenic agent with benefits that include anti-inflammatory effects and bone-conserving properties. Quercetin is suggested to protect against bone loss by inhibiting bone resorption and stimulating bone formation which is indicated by an increase in bone mineral density and bone formation markers such as osteocalcin.

The purpose of this study is to investigate the effects of quercetin supplementation on bone, specifically on bone turnover markers, in postmenopausal women. The interplay between cytokines (i.e., IL-6, CRP, and TNF-alpha) and bone turnover markers was also considered.

In a double-blind, placebo-controlled fashion, we aimed to recruit 50, healthy, postmenopausal women between the ages of 45-75 years to participate in a 90-day supplement trial. Participants will be randomly assigned to one of two supplement groups: 1) quercetin 500 mg, once per day, or 2) placebo (methyl cellulose E4M) 500 mg, once per day for 90-days.

Participants will be asked to visit the laboratory (KSU Human Performance Laboratory) on 2 separate occasions for pre- and post-testing visits consisting of body composition measurements and blood draws by a CITI approved/IRB approved research team member trained in phlebotomy under the supervision of Dr. VanDusseldorp.

Enrollment

33 patients

Sex

Female

Ages

45 to 75 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Clinically defined as postmenopausal (absence of menstrual cycle for 12 months without contraceptives or the surgical removal of the reproductive organs)
Activity levels ranging from sedentary to recreationally active were included in the study.

Exclusion criteria

Hyper- or hypothyroidism (uncontrolled)
Hyper- or hypoparathyroidism
Gastrointestinal disorders
Renal disorders
Orthopedic disorders
Rheumatological disorders
Immunological disorders
Type I diabetic
Being treated with any diabetic injectable medication(s).
Taking any non-steroidal, steroidal, or anti-inflammatory drugs
Currently, or in the past 1 month, were consuming daily calcium
Currently, or in the past 1 month, were consuming more than 5,000 IU's of vitamin D supplements
Taking any anti-obesity medications
Taking any osteoporotic medication(s)
Taking any long-term antibiotics.
Current smoker
Diagnosed with osteoporosis, or if their BMD was equal to, or fell below -2.50 via dual x-ray absorptiometry (DXA) during visit 1
Involved in heavy resistance training
Began a new unaccustomed exercise routine during the 90-days
Allergies to food(s) rich in QUE such as onions, apples, or berries; or if they were unwilling to avoid quercetin-containing foods.